SYNbiotics Easing Renal failure by improving Gut microbiologY (SYNERGY): A protocol of placebo-controlled randomised cross-over trial

BMC Nephrology

Volumn 15, Issue 1, 2014, Pages

  Rossi, Megan ^a,b,c   Johnson, David W ^a,b,c   Morrison, Mark ^a,b   Pascoe, Elaine ^a   Coombes, Jeff S ^a   Forbes, Josephine M ^b,d   McWhinney, Brett C ^e   Ungerer, Jacobus Pj ^e   Dimeski, Goce ^a,c   Campbell, Katrina L ^a,b,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b TRANSLATIONAL RESEARCH INSTITUTE   (Australia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

^d MATER MEDICAL RESEARCH INSTITUTE   (Australia)

^e Department of Nephrology Princess Alexandra Hospital ^*  (Australia)

Author keywords

Chronic kidney disease; Endotoxins; Gut microbiota; Indoxyl sulphate; P cresyl sulphate; Prebiotics; Probiotics; Synbiotics

Indexed keywords

ALBUMIN; INDOXYL SULPHATE; KIDNEY INJURY MOLECULE 1; LIPOPOLYSACCHARIDE; P CRESYL SULPHATE; PLACEBO; PREBIOTIC AGENT; PROBIOTIC AGENT; PROTEIN; SULFATE; SYNBIOTIC AGENT; TRIMETHYLAMINE OXIDE; UNCLASSIFIED DRUG; UREMIC TOXIN; BIOLOGICAL MARKER;

ALBUMINURIA; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMMUNITY STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SAFETY; ENDOTOXEMIA; FECES ANALYSIS; FECES MICROFLORA; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HUMAN; INFLAMMATION; INTERVENTION STUDY; INTESTINE FLORA; KIDNEY INJURY; KIDNEY TUBULE; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PLACEBO EFFECT; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; BLOOD; CROSSOVER PROCEDURE; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; GASTROINTESTINAL TRACT; KIDNEY FAILURE; METABOLISM; MICROBIOLOGY; MICROFLORA; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

BIOLOGICAL MARKERS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; GASTROINTESTINAL TRACT; HUMANS; MICROBIOTA; OXIDATIVE STRESS; RENAL INSUFFICIENCY; SYNBIOTICS;

EID: 84925883568     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-15-106     Document Type: Article

References (79)

1. Fecal microbiota transplantation in the treatment of clostridium difficile infections. Austin M, Mellow M, Tierney WM, Am J Med in press
2. The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression. Meijers BKI, Evenepoel P, Nephrol Dial Transplant 2011 26 759 761
3. Chronic kidney disease alters intestinal microbial flora. Vaziri ND, Wong J, Pahl M, Piceno YM, Yuan J, DeSantis TZ, Ni Z, Nguyen TH, Andersen GL, Kidney Int 2013 83 308 315
4. The Gut: the forgotten organ in Uremia? Schepers E, Glorieux G, Vanholder R, Blood Purif 2010 29 130 136
5. p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase. Watanabe H, Miyamoto Y, Honda D, Tanaka H, Wu Q, Endo M, Noguchi T, Kadowaki D, Ishima Y, Kotani S, Nakajima M, Kataoka K, Kim-Mitsuyama S, Tanaka M, Fukagawa M, Otagiri M, Maruyama T, Kidney Int 2013 83 582 592
6. Uremic toxicities of indoxyl sulpahte. Niwa T, Nagoya J Med Sci 2010 71 1 11
7. Uremic toxins induce kidney fibrosis by activating intrarenal renin-angiotensin-aldosterone system associated epithelial-to-mesenchymal transition. Sun CY, Chang SC, Wu MS, PLoS One 2012 7 34026
8. Retained organic solutes, patient characteristics and all-cause and cardiovascular mortality in hemodialysis: results from the retained organic solutes and clinical outcomes (ROSCO) investigators. Melamed ML, Plantinga L, Shafi T, Parekh R, Meyer TW, Hostetter TH, Coresh J, Powe NR, BMC Nephrol 2013 14 134
9. Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Liabeuf S, Barreto DV, Barreto FC, Meert N, Glorieux G, Schepers E, Temmar M, Choukroun G, Vanholder R, Massy ZA, Nephrol Dial Transplant 2010 25 1183 1191
10. p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Meijers BK, Claes K, Bammens B, de Loor H, Viaene L, Verbeke K, Kuypers D, Vanrenterghem Y, Evenepoel P, Clin J Am Soc Nephrol 2010 5 1182 1189
11. Indoxyl sulfate predicts cardiovascular disease and renal function deterioration in advanced chronic kidney disease. Lin CJ, Liu HL, Pan CF, Chuang CK, Jayakumar T, Wang TJ, Chen HH, Wu CJ, Arch Med Res 2012 43 451 456
12. P-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Wu IW, Hsu KH, Lee CC, Sun CY, Hsu HJ, Tsai CJ, Tzen CY, Wang YC, Lin CY, Wu MS, Nephrol Dial Transplant 2010 26 938 947
13. Indoxyl sulphate and p-cresyl sulphate: therapeutically modifiable nephrovascular toxins. Rossi M, Campbell KL, Johnson DW, OA Nephrol 2013 1 13
14. Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Yu M, Kim YJ, Kang DH, Clin J Am Soc Nephrol 2011 6 30 39
15. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Niwa T, Nomura T, Sugiyama S, Miyazaki T, Tsukushi S, Tsutsui S, Kidney Int Suppl 1997 62 23 S28
16. EPPIC (Evaluating Prevention of Progression In Chronic Kidney Disease): results from 2 Phase III, Randomized, Placebo-Controlled, Double-Blind Trials of AST-120 in Adults with CKD [Abstract]. Schulman G, Berl T, Beck GJ, Remuzzi G, Ritz E, Univ V, ASN 2012 A O1106
17. Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. Gibson GR, Probert HM, Loo JV, Rastall RA, Roberfroid MB, Nutr Res Rev 2004 17 259 275
18. Guidelines for the evaluation of probiotics in food. Joint FAO/WHO Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food. Food and Agriculture Organsization, London: Food and Agriculture Organization 2002
19. Pre-, pro-, and synbiotics: do they have a role in reducing uremic toxins? a systematic review and meta-analysis. Rossi M, Klein K, Johnson DW, Campbell KL, Int J Nephrol 2012 2012 673631
20. Treating critically ill patients with probiotics: beneficial or dangerous? Jacobi CA, Schulz C, Malfertheiner P, Gut Pathog 2011 3 2
21. Evidence based practice guidelines for the nutritional management of chronic kidney disease. Ash S, Campbell K, MacLaughlin H, McCoy E, Chan M, Anderson K, Corke K, Dumont RL, L L, Meade A, Montgomery-Johnson R, Tasker T, Thrift P, Trotter B, Nutr Diet 2007 63 33 S45
22. KDIGO 2012 clinial practice guidelines for the evaluation and management of chronic kidney disease. KDIGO, Kidney Int 2013 3
23. The interviewer-administered, open-ended diet history method for assessing usual dietary intakes in clinical research: relative and criterion validation studies. PhD Thesis. Martin G, University of Wollongong, Department of biomedical science 2004
24. Accuracy of dietary recall using the USDA five-step multiple-pass method in men: an observational validation study. Conway JM, Ingwersen LA, Moshfegh AJ, J Am Diet Assoc 2004 104 595 603 (Pubitemid 38438390)
25. A method for estimating nitrogen intake of patients with chronic renal failure. Maroni BJ, Steinman TI, Mitch WE, Kidney Int 1985 27 58 65 (Pubitemid 15130686)
26. The precision of estimating protein intake of patients with chronic renal failure. Masud T, Manatunga A, Cotsonis G, Mitch WE, Kidney Int 2002 62 1750 1756 (Pubitemid 35286283)
27. Microbiota restoration: natural and supplemented recovery of human microbial communities. Reid G, Younes JA, Van der Mei HC, Gloor GB, Knight R, Busscher HJ, Nat Rev Microbiol 2011 9 27 38
28. Role of gut bacteria in human toxicology and pharmacology. Hill M, London: Taylor & Francis 1995
29. Adhesion properties and competitive pathogen exclusion ability of bifidobacteria with acquired acid resistance. Collado MC, Gueimonde M, Sanz Y, Salminen S, J Food Prot 2006 69 1675 1679 (Pubitemid 44097973)
30. Lactobacillus strain GG supplementation decreases colonic hydrolytic and reductive enzyme activities in healthy female adults. Ling WH, Korpela R, Mykkanen H, Salminen S, Hanninen O, J Nutr 1994 124 18 23 (Pubitemid 24057432)
31. Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: a 6-month pilot scale trial in Canada. Ranganathan N, Friedman EA, Tam P, Rao V, Ranganathan P, Dheer R, Curr Med Res Opin 2009 25 1919 1930
32. Enumeration of human colonic bacteria producing phenolic and indolic compounds: effects of pH, carbohydrate availability and retention time on dissimilatory aromatic amino acid metabolism. Smith EA, Macfarlane GT, J Appl Bacteriol 1996 81 288 302
33. Baseline microbiota activity and initial bifidobacteria counts influence responses to prebiotic dosing in healthy subjects. De Preter V, Vanhoutte T, Huys G, Swings J, Rutgeerts P, Verbeke K, Aliment Pharmacol Ther 2007 27 504 513 (Pubitemid 351300850)
34. Inulin-type prebiotics-a review: part 1. Kelly G, Altern Med Rev 2008 13 315 329
35. Dietary prebitoics: current status and new defintion. Gibson G, Scott K, Rastall R, IFIS Funct Foods Bull 2010 7 1 19
36. Effects of transgalactosylated disaccharides on the human intestinal microflora and their metabolism. Ito M, Kimura M, Deguchi Y, Miyamori-Watabe A, Yajima T, Kan T, J Nutr Sci Vitaminol (Tokyo) 1993 39 279 288
37. Beneficial effects of Bifidobacteria in a gastroresistant seamless capsule on hyperhomocysteinemia in hemodialysis patients. Taki K, Takayama F, Niwa T, J Ren Nutr 2005 15 77 80 (Pubitemid 40093687)
38. Perceptions of flatulence from bean consumption among adults in 3 feeding studies. Winham DM, Hutchins AM, Nutr J 2011 10 128
39. Reference ranges and biological variation of free and total serum indoxyl- and p-cresyl sulphate measured with a rapid UPLC fluorescence detection method. Pretorius CJ, McWhinney BC, Sipinkoski B, Johnson LA, Rossi M, Campbell KL, Ungerer JP, Clin Chim Acta 2013 419 122 126
40. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, Lambotte O, Altmann D, Blazar BR, Rodriguez B, Teixeira-Johnson L, Landay A, Martin JN, Hecht FM, Picker LJ, Lederman MM, Deeks SG, Douek DC, Nat Med 2006 12 1365 1371 (Pubitemid 44924494)
41. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. Barnes PJ, Karin M, N Engl J Med 1997 336 1066 1071 (Pubitemid 27163860)
42. Protein-bound uremic toxins, inflammation and oxidative stress: a cross-sectional study in stage 3-4 chronic kidney disease. Rossi M, Campbell KL, Johnson DW, Stanton T, Vesey DA, Coombes JS, Weston KS, Hawley CM, McWhinney BC, Ungerer JP, Isbel NM, Arch Med Res in press
43. Optimized method for quantification of total F(2)-isoprostanes using gas chromatography-tandem mass spectrometry. Briskey DR, Wilson GR, Fassett RG, Coombes JS, J Pharm Biomed Anal 2014 90 161 166
44. Automated assays for superoxide dismutase, catalase, glutathione peroxidase, and glutathione reductase activity. Wheeler CR, Salzman JA, Elsayed NM, Omaye ST, Korte DW Jr, Anal Biochem 1990 184 193 199 (Pubitemid 20055611)
45. Cardiovascular implications of proteinuria: an indicator of chronic kidney disease. Agrawal V, Marinescu V, Agarwal M, McCullough PA, Nat Rev Cardiol 2009 6 301 311
46. Chronic kidney disease:national clinical guideline for early identification and management in adults in primary and secondary care. National Collaborating Centre for Chronic Conditions, London: Royal College of Physicians 2008
47. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Vaidya VS, Ozer JS, Dieterle F, Collings FB, Ramirez V, Troth S, Muniappa N, Thudium D, Gerhold D, Holder DJ, Bobadilla NA, Marrer E, Perentes E, Cordier A, Vonderscher J, Maurer G, Goering PL, Sistare FD, Bonventre JV, Nat Biotechnol 2010 28 478 485
48. Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial. Waanders F, Vaidya VS, van Goor H, Leuvenink H, Damman K, Hamming I, Bonventre JV, Vogt L, Navis G, Am J Kidney Dis 2009 53 16 25
49. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. Brazier JE, Harper R, Jones NM, O'Cathain A, Thomas KJ, Usherwood T, Westlake L, BMJ 1992 305 160 164
50. A preliminary investigation of depression and kidney functioning in patients with chronic kidney disease. Cukor D, Fruchter Y, Ver Halen N, Naidoo S, Patel A, Saggi SJ, Nephron Clin Pract 2012 122 139 145
51. Reliability and validity of the gastrointestinal symptom rating scale in patients with gastroesophageal reflux disease. Revicki DA, Wood M, Wiklund I, Crawley J, Qual Life Res 1998 7 75 83 (Pubitemid 28113967)
52. The prevalence of gastrointestinal symptoms in patients with chronic renal failure is increased and associated with impaired psychological general well-being. Strid H, Simren M, Johansson AC, Svedlund J, Samuelsson O, Bjornsson ES, Nephrol Dial Transplant 2002 17 1434 1439
53. Improved extraction of PCR-quality community DNA from digesta and fecal samples. Yu Z, Morrison M, Biotechniques 2004 36 808 812 (Pubitemid 38620199)
54. Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms. Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Huntley J, Fierer N, Owens SM, Betley J, Fraser L, Bauer M, Gormley N, Gilbert JA, Smith G, Knight R, ISME J 2012 6 1621 1624
55. QIIME allows analysis of high-throughput community sequencing data. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Pena AG, Goodrich JK, Gordon JI, Huttley GA, Kelley ST, Knights D, Koenig JE, Ley RE, Lozupone CA, McDonald D, Muegge BD, Pirrung M, Reeder J, Sevinsky JR, Turnbaugh PJ, Walters WA, Widmann J, Yatsunenko T, Zaneveld J, Knight R, Nat Methods 2010 7 335 336
56. Effects of oral adsorbent AST-120 on the progression of chronic renal failure: a randomized controlled study. Owada A, Nakao M, Koike J, Ujiie K, Tomita K, Shiigai T, Kidney Int Suppl 1997 63 188 S190
57. Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis. Takayama F, Taki K, Niwa T, Am J Kidney Dis 2003 41 142 S145
58. Design and analysis of cross-over trials. Jones B, Kenward G, London: Chapman & Hall 2003
59. Numerical ecology validates a biogeographical distribution and gender-based effect on mucosa-associated bacteria along the human colon. Aguirre de Carcer D, Cuiv PO, Wang T, Kang S, Worthley D, Whitehall V, Gordon I, McSweeney C, Leggett B, Morrison M, ISME J 2011 5 801 809
60. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimburger O, Massy Z, Clin J Am Soc Nephrol 2008 3 505 521
61. p-Cresol sulfate and indoxyl sulfate induce similar cellular inflammatory gene expressions in cultured proximal renal tubular cells. Sun CY, Hsu HH, Wu MS, Nephrol Dial Transplant 2012 28 70 78
62. Indoxyl sulfate induces nephrovascular senescence. Niwa T, Shimizu H, J Ren Nutr 2012 22 102 106
63. Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells. Motojima M, Hosokawa A, Yamato H, Muraki T, Yoshioka T, Kidney Int 2003 63 1671 1680 (Pubitemid 36513312)
64. Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. McIntyre CW, Harrison LE, Eldehni MT, Jefferies HJ, Szeto CC, John SG, Sigrist MK, Burton JO, Hothi D, Korsheed S, Owen PJ, Lai KB, Li PK, Clin J Am Soc Nephrol 2011 6 133 141
65. Effect of oral administration of freeze-dried lactobacillus acidophilus on small bowel bacterial overgrowth in patients with end stage kidney disease: reducing uremic toxins and improving nutrition. Dunn SR, Simenhoff ML, Ahmed KE, Gaughan WJ, Eltayeb BO, Fitzpatrick M-ED, Emery SM, Ayres JW, Holt KE, Int Dairy J 1998 8 545 553 (Pubitemid 28504156)
66. Bacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation. Lassenius MI, Pietilainen KH, Kaartinen K, Pussinen PJ, Syrjanen J, Forsblom C, Porsti I, Rissanen A, Kaprio J, Mustonen J, Groop PH, Lehto M, Diabetes Care 2011 34 1809 1815
67. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R, Mastrojeni S, Malaguarnera G, Mistretta A, Li Volti G, Galvano F, Dig Dis Sci 2012 57 545 553
68. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM, Hepatology 2004 39 1441 1449 (Pubitemid 38569067)
69. Understanding the mechanisms by which probiotics inhibit gastrointestinal pathogens. Corr SC, Hill C, Gahan CG, Adv Food Nutr Res 2009 56 1 15
70. Metaorganismal nutrient metabolism as a basis of cardiovascular disease. Brown JM, Hazen SL, Curr Opin Lipidol 2014 25 48 53
71. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, Wu Y, Li L, Smith JD, DiDonato JA, Chen J, Li H, Wu GD, Lewis JD, Warrier M, Brown JM, Krauss RM, Tang WH, Bushman FD, Lusis AJ, Hazen SL, Nat Med 2013 19 576 585
72. Biochemical profile or uremic breath. Simenhoff ML, Burke JF, Saukkonen JJ, Ordinario AT, Doty R, N Engl J Med 1977 297 132 135
73. Association between depression and death in people with CKD: a meta-analysis of cohort studies. Palmer SC, Vecchio M, Craig JC, Tonelli M, Johnson DW, Nicolucci A, Pellegrini F, Saglimbene V, Logroscino G, Hedayati SS, Strippoli GF, Am J Kidney Dis 2013 62 493 505
74. The microbiota-gut-brain axis: neurobehavioral correlates, health and sociality. Montiel-Castro AJ, Gonzalez-Cervantes RM, Bravo-Ruiseco G, Pacheco-Lopez G, Front Integr Neurosci 2013 7 70
75. Prebiotic feeding elevates central brain derived neurotrophic factor, N-methyl-d-aspartate receptor subunits and d-serine. Savignac HM, Corona G, Mills H, Chen L, Spencer JPE, Tzortzis G, Burnet PWJ, Neurochem Int 2013 63 756 764
76. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, Bienenstock J, Cryan JF, Proc Natl Acad Sci U S A 2011 108 16050 16055
77. Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. Ranganathan N, Ranganathan P, Friedman EA, Joseph A, Delano B, Goldfarb DS, Tam P, Venketeshwer Rao A, Anteyi E, Guido Musso C, Adv Ther 2010 27 634 647
78. The international scientific conference on probiotics and prebiotics. Madsen K, Expert Rev Gastroenterol Hepatol 2011 5 571 573
79. Very low protein diet reduces indoxyl sulfate levels in chronic kidney disease. Marzocco S, Dal Piaz F, Di Micco L, Torraca S, Sirico ML, Tartaglia D, Autore G, Di Iorio B, Blood Purif 2013 35 196 201